Oxytocin vs Prostamax
A side-by-side research comparison of Oxytocin and Prostamax across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Oxytocin | Prostamax |
|---|---|---|
| Full name | Oxytocin (OXT) | Prostamax (Prostate Peptide Bioregulator) |
| Category | Sexual Health | Sexual Health |
| Status | FDA Approved | Research compound (peptide bioregulator) |
| Mechanism | Binds OXTR in social cognition brain regions (amygdala, nucleus accumbens) and reproductive organs. Modulates serotonin and dopamine in reward circuits. | As a signal peptide, it is proposed to regulate gene expression in prostate tissue, supporting normal prostatic function, reducing inflammation-related dysfunction, and maintaining healthy urogenital tissue. |
| Molecular weight | 1,007 Da | ~ (short peptide) |
| Half-life | 3-5 min (IV) / 20-30 min (intranasal) | Short (peptide) |
| Bioavailability | Low (oral), Moderate (intranasal ~2-5%) | Oral (encapsulated) or subcutaneous |
| Typical dose | 20-40 IU intranasal | ~1-2 capsules/day or short injectable courses |
| Frequency | As needed or daily | Once daily |
| Route | Intranasal or IV (obstetric) | Oral capsule or subcutaneous |
Oxytocin reported benefits
- Enhanced social bonding
- Improved intimacy
- Anxiolytic effects
- Pain modulation
- Post-orgasmic well-being
Prostamax reported benefits
- Prostate tissue support (proposed)
- Male urogenital health
- Anti-inflammatory tissue signaling (proposed)
- Short course-based protocol
Related comparisons
Research and educational reference only. Not medical advice.